Chien-Chien Jacques Appointed CFO at Rooster Bio RoosterBio, a Frederick-based leader in stem cell and exosome technologies, has appointed Chien-Chien “CC” Jacques as its new CFO, where she will oversee [….]
Buzzin’ Brood: Student Spotlight, Sarah Shah, HS Get to know Sarah Shah, from Frederick, MD, is a student at Urbana High School, Class of 2025. She is actively involved in [….]
11 Women in the Life Sciences That You Should Know in the BioHealth Capital Region In honor of Women’s History Month, which kicks off today, we wanted to highlight 11 [….]
Since its inception, MSCRF has invested over $170 million in over 500 projects to accelerate stem cell research, commercialization, and cures. With a 2023 fiscal year budget of $20.5M, MSCRF offers six funding opportunities to scientists and companies in the areas of clinical trials, discovery, commercialization, validation, launch, and post-doctoral fellowships. The fund has supported the creation and growth of many stem cell companies since launching the Accelerating Cures initiative in 2017.
The Maryland Stem Cell Research Commission announced it will grant $7,067,409 in award funding to innovative research that will strengthen and advance stem cell treatments and technologies in Maryland. Awardees submitted proposals to the Commission in response to its Request for Applications (RFAs) for its second round of funding cycle in 2022.
The Maryland Stem Cell Research Commission (Commission) has approved funding to its second round of 2021 recipients for a total of $6,052,901. The Commission has also appointed Amritha Jaishankar, Ph.D., the current MSCRF Director – Programs & Strategic Alliances, to succeed Dan Gincel, Ph.D., as Executive Director of the MSCRF, effective May 14, 2021.
At Maryland Lifesciences’ 2020 Bio Innovation Conference, American Gene Technologies (AGT) took center stage. AGT was the virtual event’s diamond sponsor, AGT’s CEO and Founder Jeff Galvin kicked off the event with opening remarks and then hosted several panel discussions, including “Expanding Progress and Opportunities in Gene and Cell Therapy,” which was a highlight of the conference’s second day.
Perhaps the single biggest challenge faced by startup entrepreneurs and early-stage life science companies is securing the necessary funding to fuel innovation and growth. The BioHealth Capital Region (BHCR) life science community as a whole faces a similar challenge when it comes to access to venture capital funding; this challenge has been noted by many BHCR thought leaders and well-documented in a host of BioBuzz stories.
Stem Cell Experts from Maryland presenting at Phacilitate World Stem Cell Summit
Cell Therapy to Replace All Modern Medicine? In order: Phil Vanek, PhD (GE Healthcare); Claudia Zylberberg, PhD (Akron Biotechnology); Joshua Hare, MD (Longeveron); Doug Doerfler (Maxcyte) participate in the “Realizing [….]
